
Telesis Bio Investor Relations Material
Latest events

Q2 2023
Telesis Bio

Q3 2024
7 Nov, 2024

Q2 2024
7 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Telesis Bio Inc
Access all reports
Telesis Bio Inc. is a synthetic biology company that provides automated solutions for DNA and RNA synthesis. Its core product, the BioXp system, is the world’s first fully automated gene synthesis platform, enabling researchers to rapidly design, build, and clone high-quality synthetic DNA and mRNA. Telesis Bio's technologies are widely used in various applications, including vaccine development, gene and cell therapy, precision medicine, and biologics drug discovery. Telesis Bio is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
DNAY
Country
🇺🇸 United States